Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dutasteride + tamsulosin hydrochloride** is a fixed-dose combination medication used in the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. The combination consists of two pharmacologically distinct drugs: **dutasteride**, a dual 5-alpha-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT), thereby decreasing prostate size; and **tamsulosin hydrochloride**, a selective alpha-1 adrenergic receptor antagonist that relaxes the smooth muscle in the prostate and bladder neck to improve urinary flow. This combination provides more effective relief of BPH symptoms and reduces disease progression compared with monotherapy. It is taken orally, typically as a single daily capsule, and studied under the brand name Jalyn, among others.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dutasteride + tamsulosin hydrochloride.